small nuclear ribonucleoprotein polypeptide G pseudogene 9Genealiases: []
Q-omics provides the consensus-scored SNRPGP9 profile across patient tissues and cancer cell-line models. SNRPGP9 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SNRPGP9 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, SNRPGP9 RNA expression shows 12,072 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, HNSC, and THYM as cancer lineages where SNRPGP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRPGP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRPGP9 survival associations across molecular data types. SNRPGP9 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRPGP9 RNA expression–survival associations across cancer types. High SNRPGP9 expression shows unfavorable associations in ACC, UCEC, KICH, BRCA, STAD and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SNRPGP9 RNA expression.
This table summarizes SNRPGP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNRPGP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRPGP9 shows lower tumor expression in KICH and higher tumor expression in HNSC, BLCA, LUSC, BRCA and LUAD. The HNSC box plot shows higher SNRPGP9 RNA expression in tumor versus normal tissue (log2 FC = +0.779, t-test p < 0.001).
This table shows molecular features associated with SNRPGP9 in patient tissues and cancer cell lines. In patient samples, SNRPGP9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
